Last updated 4 days ago
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
600 patients around the world
Available in Puerto Rico, Argentina, United States, Mexico
Eli Lilly and Company
11Research sites
600Patients around the world
This study is for people with
Obesity
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Have body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or BMI ≥25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening.Hypertension.Dyslipidemia.Obstructive sleep apnea.Cardiovascular disease.Have a history of at least one unsuccessful dietary effort to lose body weight.
- Have type 1 diabetes, type 2 diabetes, or any other types of diabetes.Have an unstable body weight within 90 days prior to screening.Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening.Have acute or chronic hepatitis or pancreatitis.Are taking other medications or alternative remedies to manage weight loss.
Sites
Centro Médico Viamonte SRL - CABA, Buenos Aires
Instituto Centenario
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Centro de Diagnóstico y Rehabilitación - CEDIR
Centro de Alergia y Enfermedades Respiratorias - Buenos Aires
Instituto Medico Catamarca "IMEC"
RM Pharma Specialists S.A. de C.V.
Köhler & Milstein Research
Diseño y Planeación en Investigación Médica
Centro Médico Zambrano Hellion
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Obesity
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06972459
